Shattuck Labs (NASDAQ:STTK) reported quarterly losses of $(0.65) per share. This is a 16.07 percent decrease over losses of $(0.56) per share from the same period last year.
Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $8
Morgan Stanley analyst Michael Ulz maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $35 to $8.